Supira Medical

A Very Small Pump, and the Very Large Sum Betting On It

How a Shifamed spinout in Los Gatos convinced sovereign wealth to fund a heart pump that isn't on the market yet.

Here is a fact about the heart-pump business that sounds like a joke but is actually the entire business: the hard part is not the pumping. We have known how to move blood mechanically for decades. The hard part is getting the pump into a human being without wrecking the artery you pushed it through, and then getting it back out again. Supira Medical, a clinical-stage company in Los Gatos, California, has organized its entire existence around that second problem, and in March 2025 a group of investors that included Qatar's sovereign wealth fund decided the effort was worth $120 million.

That is the kind of sentence that deserves a second look. Supira does not have a product you can buy. It has a device, the Supira System, that is still working its way through clinical trials. It has, by public estimates, something like $11 million of annual revenue, which for a company that has raised roughly a quarter of a billion dollars is less "revenue" and more "rounding error." And yet Novo Holdings, the investment arm behind one of the largest pharmaceutical fortunes on earth, and the Qatar Investment Authority co-led an oversubscribed round. Oversubscribed means more people wanted in than there was room for. People were, in other words, competing to give this company money.

Why? The short answer is that in medical devices the moat is not the idea. The idea - a percutaneous ventricular assist device, or pVAD - already exists in the market, most famously as the Impella pumps sold by Abiomed, now part of Johnson & Johnson. The moat is the clinical data proving your version is better, and that data is expensive, slow, and legally required. When you fund Supira, you are not really funding a gadget. You are funding the multi-year, patient-by-patient process of generating evidence that the U.S. Food and Drug Administration will accept. The evidence is the product. The pump is just the thing the evidence is about.

What the device actually does

Strip away the acronyms and here is the situation. Sometimes a heart cannot keep up. This happens in two very different circumstances that Supira has chosen to chase with a single device. The first is planned: a high-risk percutaneous coronary intervention, or HRPCI, where a cardiologist is doing delicate work on a diseased artery and needs the heart to keep the body alive while its own plumbing is temporarily compromised. The second is a crisis: cardiogenic shock, where the heart has failed so badly that it can no longer push enough blood to keep the patient going, and the clock is measured in minutes.

In both cases you want a pump that slides in through the leg, threads up to the heart, and takes over some of the pumping. The catch is a genuine engineering trade-off that has shaped this entire category: bigger pumps move more blood but require a bigger hole to insert, and a bigger hole means more risk of damaging the artery. Supira's pitch is that it has bent that curve. Its device runs at a 10F profile - "French" is the catheter sizing scale, and 10F is roughly 3.3 millimeters, about the width of a coffee stirrer - while still delivering high continuous flow. Small access, big output. If it works reliably, that is the ballgame.

There are a couple of other touches worth noting, because they tell you how the company thinks. The device carries onboard sensors that read blood pressure in real time while it is running, which matters because a clinician supporting a failing heart is otherwise partly flying blind. And it uses a flexible cannula and a particular impeller arrangement meant to keep the thing stable once it is in place. None of this is marketing poetry. It is the unglamorous list of things that either work inside a human heart or do not.

The Shifamed thing

Supira did not begin in a garage, and the fact that it didn't is one of the more interesting things about it. It was incubated inside Shifamed, a medical innovation hub founded by the serial entrepreneur Amr Salahieh, who now chairs Supira's board. Shifamed's model is roughly the opposite of the founder mythology Silicon Valley likes to sell. Instead of two people and a dream, you get a structured environment designed to take on very hard cardiovascular problems, de-risk them methodically, and spin out companies once they are far enough along to stand on their own. Supira is one of those spinouts.

Running it is Dr. Nitin Salunke, who became president and CEO in February 2020 and whose resume is a tour of the medical-device establishment: vice president of R&D for Medtronic's neurovascular business, before that R&D leadership at Altura Medical and at Cordis, the Johnson & Johnson company. He is, in other words, an engineer who became a chief executive, and in interviews he has described his operating philosophy in almost boringly sound terms: de-risk, then execute. This is the correct philosophy for a company whose product goes inside a failing human heart. A heart pump does not reward optimism. It rewards the people who assume every component will eventually fail and design around that assumption in advance.

Follow the money

The funding history is a tidy little escalator: a $35 million Series B in 2020, a $30 million Series C in 2021, a $40 million Series D in 2022 that arrived alongside an FDA Breakthrough Device Designation, and then the $120 million Series E in March 2025. That last round is the one that changes the character of the company. Breakthrough Device Designation, by the way, is the FDA signaling that a device could meaningfully improve treatment for a serious condition and therefore deserves a faster review - useful validation, though not the same thing as approval.

What is striking about the Series E is the investor list. New money came from Novo Holdings and the Qatar Investment Authority, joined by returning backers like Cormorant Asset Management, The Capital Partnership, 415 Capital, AMED Ventures, the PA MedTech VC Fund, and Unorthodox Ventures. Sovereign wealth funds and blue-chip life-sciences investors do not typically show up for pre-commercial medtech unless they think the eventual market is very large and the technical risk is being genuinely retired. Their presence is itself a data point.

And the money has a job. Supira has said the Series E funds its clinical programs for both indications, including the SUPPORT II U.S. pivotal study for high-risk PCI, which is the study designed to support a PMA - premarket approval - submission to the FDA. PMA is the demanding regulatory pathway reserved for the highest-risk devices, the ones where the agency wants to see real clinical proof before letting you sell. Getting there is the whole point.

Where it stands now

In its March 2025 announcement, Supira said it had completed enrollment of its SUPPORT I Early Feasibility Study in the United States - a small first-in-U.S.-humans study, 15 patients across four clinical sites, evaluating safety and feasibility in patients undergoing high-risk PCI. Fifteen patients is not a lot, and it is not supposed to be. Feasibility studies are the cautious first knock on the door. Then, in April 2026, the company announced that the FDA had approved initiation of the SUPPORT II pivotal trial and reported progress on its cardiogenic shock program, along with the appointment of the medtech veteran D. Keith Grossman to its board. The pivotal trial is the big one, the study whose results a PMA submission would rest on. It is the difference between a promising device and a product.

So what can you actually do with Supira today? If you are a patient, nothing yet - it is not commercially available, and it should not be, because the entire apparatus of trials and approvals exists precisely so that "not yet" comes before "for sale." If you are an interventional cardiologist at one of the trial sites, you can participate in generating the evidence. And if you are watching the mechanical circulatory support market, you can note that the incumbent finally has a well-funded, technically credible, single-platform challenger aiming at both of its core indications at once.

That last ambition - one device for both a planned procedure and an emergency - is the part most companies would avoid, because focusing on one indication is easier and cleaner. Supira is doing the harder thing on purpose. Whether that is discipline or hubris is exactly the question the pivotal trial exists to answer. For now, the company has done the two things a clinical-stage medtech company is supposed to do: it has raised the money, and it has earned the right to run the study that matters. The rest is data, collected the slow way, one heart at a time.